Modern ossibilities of metabolic therapy – actovegin in focus.

Modern ossibilities of metabolic therapy – actovegin in focus.

Prof. Kochueva M.N., PHD Kochuyev G.I., prof. Korzh O.M., PHD Krasnokutskiy S.V., Plyehova O.O. Kharkiv Medical Academy of Postgraduate Education. Kharkiv National Medical University.

There view shows them ain pharmacological properties and mechanisms of actionof Actovegin — metabolic pharmacological agents. Based on the analysis of clinical studies in vestigated the effectiveness of Actovegin in patients with acute and chroniccer ebrovascular in sufficiency, diabetic encephalopathy, diabetic vascular lesions of the lower limbs, Alzheimer’s disease and other pathologies.

Key Words: Actovegin, diabet, Alzheimer’s disease.

Kochueva MN, Kochuyev GI, Korzh OM, Krasnokutskiy SV, Plyehova OO. [Modern ossibilities of metabolic therapy – actovegin in focus]. Shidnoevr. z. vnutr. simejnoi med. 2015;1:101-108. Russian.
http://dx.doi.org/10.15407/internalmed2015.01.101

 Download.PDF

1. Kovalenko VM, Kornatskyi VM. Dynamika stanu zdorov`ia narodu Ukrainy ta rehionalni osoblyvosti. Analitychno-statystychnyi posibnyk. [Dynamics of health status of Ukrainian population and regional features]. 2013 p. Ukrainian
2. Gromova OA, Panasenko OM, Skalnyi AV. Neirokhimicheskie mekhanizmy deistviia sovremennykh neiroprotektorov prirodnogo proiskhozhdeniia (elementnyi analiz i fermentativnaia antiokislitelnaia aktivnost). Aktovegin. Novye aspekty klinicheskogo primeneniia. [Neurochemical mechanisms of action of modern neuroprotectors of natural origin (element analysis and enzyme antioxydant activity). Actovegin. New aspects of clinical application]. M.; 2002. Russian
3. Cheraskin E. [Antioxidants in health and disease]. J Am OptomAssoc. 1996; 67 (1): 50-57. English
4. Obermaier-Kuser B, Muchibacher Ch, Mushack J. [Further evidence for afwo-step model of glucose transport regulation]. Biochem J. 1989; 261: 699—705. English
http://dx.doi.org/10.1042/bj2610699
5. Nordvik B. Mekhanizm deistviia i klinicheskoe primenenie preparata aktovegina. Aktovegin. Novye aspekty klinicheskogo primeneniia. [Mechanism of action and clinical application of actovegin. Actovegin. New aspects of clinical usage]. M.; 2002. 18—24 p. English
6. Fedorovich AA, Rogoza AN, Kanishcheva EM, Boitsov SA. Vliianie preparata aktovegin na metabolicheskuiu i vazomotornuiu funktsiiu mikrososudistogo endoteliia kozhi cheloveka. RFK. [Influence of actovegin on metabolic and vasomotor function of microvascular endothelium of human skin]. 2010; (6): 53—60. Russian
7. Neverov IV. Mesto antioksidantov v kompleksnoi terapii pozhilykh bolnykh IBS. [Place of antioxydants in coplex therapy of elderly patients with IHD]. RMZh. 2001; 9 (18): 17-21. Russian
8. Bagchi D, Sen CK, Ray SD, Das DK, Bagchi M, Preuss HG, Vinson JA. [Molecular mechanisms of cardioprotection with a novel grape seed proanthocyanidin extract]. MutatRes. 2003; 523: 87-97. English
http://dx.doi.org/10.1016/S0027-5107(02)00324-X
9. Gorshkov IP, Zoloedov VI, Volynkina AP. Klinicheskaia effektivnost Aktovegina v korrektsii oksidativnogo stressa pri diabeticheskoi polineiropatii u bolnykh sakharnym diabetom 2-go tipa s arterialnoi gipertenziei. [Clinical effectiveness of actovegin in correction of oxidative stress in case of diabetic polyneuropathy in patients with diabetes of II type with arterial hypertension]. Sakharnyi diabet. 2010; (2): 84-89. Russian
10. Astashkin EI, Glezer MG, Orekhova NS. Vliianie aktovegina na fagotsity krovi pri oksidativnom stresse u patsientov s serdechnoi nedostatochnostiu. [Influence of actovegin on blood phagocytes in oxidative stress in patients with heart failure]. Farmateka. 2014; (9): 14-19. Russian
11. Jansen W, Beck E. [Treatment of diabetic polyneuropathy. A controlled double blind study]. Med. Welt. 1987; 38: 838—841. English
12. Ziegler D, Movsesyan L, Mankovsky B. [Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients]. Diabetes Care. 2009; Vol. 32 (8): 1479—1484. English
http://dx.doi.org/10.2337/dc09-0545
13. Gureva IV, Begma IV, Kuzina IV. Patogeneticheskoe lechenie Aktoveginom neiroishemicheskogo bolevogo sindroma nizhnikh konechnostei pri sakharnom diabete. [Pathogenetic treatment of neuroishemic syndrome of lower extremities in diabetes mellitus with actovegin]. RMZh. 2009; (10): 670—672. Russian
14. Ametov AS, Morgoeva FE, Strokov IA. Diabeticheskaia entsefalopatiia i polinevropatiia: terapevticheskie vozmozhnosti Aktovegina. [Diabetic encephalopathy and polyneuropathy: therapeutic oppottunities of actovegin]. RMZh. 2005; (6): 302—304. Russian
15. Krotovskii GS, Zudin AN, Uchkin IG. Medikamentoznoe lechenie khronicheskoi ishemii nizhnikh konechnostei. [Medicamental treatment of chronic ischemia of lower extremities]. RMZh. 2010; (17): 1046—1050. Russian
16. Anikin AI, Stupin VA, Goriunov SV. Kompleksnoe khirurgicheskoe lechenie bolnykh s gnoino-nekroticheskimi porazheniiami na fone sindroma diabeticheskoi stopy. [Complex surgical treatment of patients with purulent and necrotic lesions on the background of diabetic foot syndrome]. RMZh. 2010; (17): 1055—1059. Russian
17. Krivikhin VT, Krivikhin DV, Ambrosimova OS. Kompleksnaia terapiia sindroma diabeticheskoi stopy u bolnykh sakharnym diabetom 2 tipa s gnoino-nekroticheskimi porazheniiami nizhnikh konechnostei. [Complex therapy of diabetic foot syndrome in patients with diabetes of 2 type with purulent-necrotic lesions of lower extremities]. 2011; (10): 70—74. Russian
18. Naumov AV, Danchinova AA, Molokov VA, Skorikova IS. Neiroprotektivnaia terapiia: nachalo otscheta — dogospitalnyi etap. [Neuroprotective therapy: count start – prehospital stage]. /www.cito03.ru/jurnal/nt/nt_2008/ nt-2008aa17aa.pdf Russian
19. Drozdova EA. Primenenie aktovegina i tseraksona dlia korrektsii kognitivnykh narushenii pri legkoi cherepno-mozgovoi travme. [Use of actovegin and ceraxone for correction of cognitive disorders in case of mild cranial and brain trauma]. Farmateka. 2011; (14): 52—56. Russian
20. Saletu B, Grünberger J, Linzmayer L. [EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusion with the impairment after acute and 2-week infusion with the hemoderivative actovegin: doubleblind, placebo-controlled trials]. Neuropsychobiology. 1990— 1991; 24 (3): 135—148. English
21. Jansen W, Brueckner GW. [Treatment of chronic cerebrovascular diseases with Actovegin forte]. Therapiewoche. 1982; 41: 3—12. English
22. Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Infusion therapie mit actovegin bei patienten mit primar degenerativer demenzvom Alzheimer typ und multiinfarkt-demenz. [Infusion therapy with actovegin in patients with degenerative primary dementia of Alzheimer type and multi-infarct dementia]. Z. Geriatrie. 1992; 5: 46—55. German
23. Oswald WD, Steger W, Oswald B. [Increase of fluid cognitive components as an aspect in evaluation drug efficacy. A double-controlled study with Actovegin]. ZeitschriftGerontopsychol. Psichiatr. 1991; 4 (4): 209—220. English
24. Rumjanceva SA, Fedin AI. Nevrologicheskie rasstrojstva pri sindrome poliorgannoj nedostatochnosti. [Neurological disorders in syndrome of multiple organ failure]. M.: RKI Soveropress. 2002. 252 p. Russian
25. Stahovskaja LV, Efremova NM, Shamalov NA. Issledovanie bezopasnosti i jeffektivnosti kombinirovannoj terapii citikolinom i Aktoveginom bol’nyh v ostrom periode ishemicheskogo insul’ta. [Investigation of safety and effectiveness of combined therapy with citicoline and actovegin for patients in acute period of ishemic stroke]. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2010; (9): 13—17. Russian
26. Afanasev VV, Rumiantseva SA, Kuzmina IV, Silina EV. Ratsionalnaia farmakokorrektsiia porazhenii mozga pri ostroi i khronicheskoi ishemii. [Rational pharmacological correction of brain disorders in acute and chronic ischemia]. Consilium Medicum. 2010; (9): 35—38. Russian
27. Chukanova EI. Aktovegin v lechenii bolnykh s distsirkuliatornoi entsefalopatiei. [Actovegin in treatment of patients with dyscirculatory encephalopathy]. Farmateka. 2005; 17: 71— 76. Russian
28. Ostroumova OD, Bobrova LS. Vozmozhnosti aktovegina v uluchshenii kognitivnykh funktsii u patsientov s sosudistymi zabolevaniiami golovnogo mozga. [Opportunities of actovegin in correction of cognitive function in patients with vascular diseases of brain]. Atmosfera. Nervnye bolezni. 2006; (3): 28—32. Russian
29. Morgoeva FE, Ametov A, Strokov IA. Diabeticheskaia entsefalopatiia i polinevropatiia: terapevticheskie vozmozhnosti aktovegina. [Diabetic encephalopathy and polyneuropathy: therapeutical opportunities of actovegin]. Rus. med. zhurn. 2005; (6): 02— 304. Russian
30. Chugunov AV, Kamchatnov PR, Kabanov AA. Vozmozhnosti metabolicheskoi terapii u bolnykh s khronicheskimi rasstroistvami mozgovogo krovoobrashcheniia. [Opportunities of metabolic therapy in patients with chronic disorders of brain circulation]. Consilium Medicum. 2006; 2: 27-29.
31. Elmlinger MW, Kriebel M and Ziegler D. [Neuroprotective and antioxidative effects of the hemodialysate actovegin on primary rat neurons in vitro]. Neuromolecular Med. 2011; 13: 266-274. Russian
http://dx.doi.org/10.1007/s12017-011-8157-7
32. Guekht et al. [A randomised, double-blind, placebocontrolled trial of actovegin in patients with poststroke cognitive impairment: ARTEMIDA study design]. Dement Geriatr Cogn Disord Extra 2013; 3: 459—467.English
http://dx.doi.org/10.1159/000357122